EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The mRNA and protein levels of the glycolytic enzymes lactate dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) are good predictors of survival time, recurrence, and risk of death in cervical cancer patients

Verónica Bolaños-Suárez iD, Ana Alfaro, Ana María Espinosa, Ingrid Medina-Martínez, Eligia Juárez, Nicolás Villegas-Sepúlveda, Marco Gudiño-Zayas iD, América Gutiérrez-Castro, Edgar Román-Bassaure, María Eugenia Salinas-Nieves, Sergio Bruno-Muñoz, Carlos Aranda und 2 weitere

Cancer Medicine · 2023-07 · 12 (14) · 15632-15649

DOI: 10.1002/cam4.6123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 16.06.2023. Verfasst von Verónica Bolaños-Suárez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. Hauptthemen laut MEDLINE: Phosphofructokinases, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Ciencia y Tecnología.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with cervical cancer (CC) may experience local recurrence very often after treatment; when only clinical parameters are used, most cases are diagnosed in late stages, which decreases the chance of recovery. Molecular markers can improve the prediction of clinical outcome. Glycolysis is altered in 70% of CCs, so molecular markers of this pathway associated with the aggressiveness of CC can be identified.

Methods

The expression of 14 glycolytic genes was analyzed in 97 CC and 29 healthy cervical tissue (HCT) with microarray; only LDHA and PFKP were validated at the mRNA and protein levels in 36 of those CC samples and in 109 new CC samples, and 31 HCT samples by qRT–PCR, Western blotting, or immunohistochemistry. A replica analysis was performed on 295 CC from The Cancer Genome Atlas (TCGA) database.

Results

The protein expression of LDHA and PFKP was associated with poor overall survival [OS: LDHA HR = 4.0 (95% CI = 1.4–11.1); p = 8.0 × 10 −3 ; PFKP HR = 3.3 (95% CI = 1.1–10.5); p = 4.0 × 10 −2 ] and disease‐free survival [DFS: LDHA HR = 4.5 (95% CI = 1.9–10.8); p = 1.0 × 10 −3 ; PFKP HR = 3.2 (95% CI = 1.2–8.2); p = 1.8 × 10 −2 ] independent of FIGO clinical stage, and the results for mRNA expression were similar. The risk of death was greater in patients with overexpression of both biomarkers than in patients with advanced FIGO stage [HR = 8.1 (95% CI = 2.6–26.1; p = 4.3 × 10 −4 ) versus HR = 7 (95% CI 1.6–31.1, p = 1.0 × 10 −2 )] and increased exponentially as the expression of LDHA and PFKP increased.

Conclusions

LDHA and PFKP overexpression at the mRNA and protein levels was associated with poor OS and DFS and increased risk of death in CC patients regardless of FIGO stage. The measurement of these two markers could be very useful for evaluating clinical evolution and the risk of death from CC and could facilitate better treatment decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhosphofructokinasesUterine Cervical NeoplasmsFemaleHumansBiomarkersGlycolysisL-Lactate DehydrogenaseLactate Dehydrogenase 5RNA, Messenger

Stichwörter der Autor:innen

cervical cancerglycolysislactate dehydrogenase A (LDHA)phosphofructokinase platelet (PFKP)risk of deathsurvival

Substanzen

BiomarkersL-Lactate DehydrogenaseLactate Dehydrogenase 5PhosphofructokinasesRNA, MessengerLDHA protein, human

Autor:innen und Institutionen

  • Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
  • Posgrado en Ciencias Biológicas, Unidad de Posgrado, Edificio D, 1° Piso, Circuito de Posgrados, Universidad Nacional Autónoma de México, Mexico City, Mexico.
  • Anatomía Patológica, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico.
  • Farmacología Clínica, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico.
  • Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
  • Unidad de Medicina Genómica, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico.

ORCID-Profile: Verónica Bolaños-Suárez, Marco Gudiño-Zayas, Jaime Berumen

Förderung

  • Consejo Nacional de Ciencia y Tecnología

Zitieren

APA

Bolaños-Suárez, V., Alfaro, A., Espinosa, A. M., Medina-Martínez, I., Juárez, E., Villegas-Sepúlveda, N., Gudiño-Zayas, M., Gutiérrez-Castro, A., Román-Bassaure, E., Salinas-Nieves, M. E., Bruno-Muñoz, S., Aranda, C., Flores-Herrera, O., & Berumen, J. (2023). The mRNA and protein levels of the glycolytic enzymes lactate dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) are good predictors of survival time, recurrence, and risk of death in cervical cancer patients. Cancer Medicine, 12(14), 15632-15649. https://doi.org/10.1002/cam4.6123

Vancouver

Bolaños-Suárez V, Alfaro A, Espinosa AM, Medina-Martínez I, Juárez E, Villegas-Sepúlveda N, et al. The mRNA and protein levels of the glycolytic enzymes lactate dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) are good predictors of survival time, recurrence, and risk of death in cervical cancer patients. Cancer Medicine. 2023;12(14):15632-15649. doi:10.1002/cam4.6123

BibTeX
@article{BolaosSurez2023,
  author = {Bolaños-Suárez, Verónica and Alfaro, Ana and Espinosa, Ana María and Medina-Martínez, Ingrid and Juárez, Eligia and Villegas-Sepúlveda, Nicolás and Gudiño-Zayas, Marco and Gutiérrez-Castro, América and Román-Bassaure, Edgar and Salinas-Nieves, María Eugenia and Bruno-Muñoz, Sergio and Aranda, Carlos and Flores-Herrera, Oscar and Berumen, Jaime},
  title = {The mRNA and protein levels of the glycolytic enzymes lactate dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) are good predictors of survival time, recurrence, and risk of death in cervical cancer patients},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {14},
  pages = {15632--15649},
  doi = {10.1002/cam4.6123}
}
Kostenlos starten →